Jasper Therapeutics, Inc. - Class A Common Stock Share · US4718712023 · JSPR (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Jasper Therapeutics, Inc. - Class A Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

01.05.2026 20:00

Current Prices from Jasper Therapeutics, Inc. - Class A Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	JSPR	USD	01.05.2026 20:00	0,93 USD	-0,006 USD -0,61 %
IEX	JSPR	USD	01.05.2026 19:45	0,94 USD	0,007 USD +0,73 %

Share Float & Liquidity

Free Float 84,78 %

Shares Float 13,78 M

Shares Outstanding 16,25 M

Company Profile for Jasper Therapeutics, Inc. - Class A Common Stock Share

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.